Your browser doesn't support javascript.
loading
Topiramate decreases the salience of motivationally relevant visual cues among smokers with alcohol use disorder.
Robinson, Jason D; Cui, Yong; Karam-Hage, Maher; Kypriotakis, George; Versace, Francesco; Ait-Daoud Tiouririne, Nassima; Anthenelli, Robert M; Cinciripini, Paul M.
Afiliação
  • Robinson JD; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Cui Y; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Karam-Hage M; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kypriotakis G; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Versace F; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ait-Daoud Tiouririne N; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Anthenelli RM; Department of Psychiatry, Pacific Treatment and Research Center, University of California, San Diego, Health Sciences, La Jolla, California, USA.
  • Cinciripini PM; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alcohol Clin Exp Res ; 46(3): 384-395, 2022 03.
Article em En | MEDLINE | ID: mdl-35037278
ABSTRACT

BACKGROUND:

There is preliminary evidence that the anticonvulsant topiramate increases the likelihood of both smoking and alcohol abstinence among smokers with alcohol use disorder (AUD), but its therapeutic mechanism has not been determined. We used event-related potentials (ERPs) to evaluate topiramate's effect on the salience of drug-related, emotional, and neutral pictorial cues to identify whether one of its potential therapeutic mechanisms involves reduction of the salience of motivationally relevant cues.

METHODS:

Participants enrolled in a multisite clinical trial treating smokers with AUD were randomly assigned to receive placebo, low-dose topiramate (up to 125 mg/day), or high-dose topiramate (up to 250 mg/day), along with brief behavioral compliance enhancement treatment. A subsample (n = 101) completed ERP assessments at baseline (1 week pre-medication) and week 5 (5 weeks on medication; 1 week pre-quit). We assessed the salience of pleasant, unpleasant, cigarette-related, alcohol-related, and neutral pictorial cues using the late positive potential (LPP) ERP component and measured self-reported substance use, reinforcement, craving, and withdrawal.

RESULTS:

Five weeks of high-dose topiramate treatment decreased LPP amplitudes in response to both emotional (pleasant and unpleasant) and drug-related cues (alcohol and cigarette), but not to neutral cues. However, results showed that the LPPs were not significant mediators of the relationship between topiramate dose and post-quit measures of substance use, reinforcement, craving, or withdrawal.

CONCLUSIONS:

These findings suggest that high-dose topiramate (up to 250 mg/day) decreases the motivational salience of both drug-related and emotional cues among smokers with AUD. However, the nonsignificant mediation analyses preclude any firm conclusions about whether this effect represents one of topiramate's therapeutic mechanisms of action.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Alcoolismo / Fumantes Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Alcoolismo / Fumantes Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article